Research ArticleResveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats
Introduction
In cirrhosis, the initial factor determining the onset of portal hypertension is the increase in intrahepatic vascular resistance. This is not only due to morphological changes resulting from chronic liver inflammation and fibrosis, but also to reversible functional alterations, including an exaggerated response of the porto-hepatic vascular bed to vasoconstrictors and a deficient response to vasodilators [1]. A decreased nitric oxide (NO) availability and an increase in cyclo-oxygenase-1 (COX-1)-derived prostanoids within the liver play a major role in the pathogenesis of these dynamic alterations [2], [3], [4], [5].
Reduced NO availability has been shown to be in part due to an increase scavenging by superoxide () and different strategies aimed at reducing levels [6], [7], such as superoxide dismutase (SOD) gene transfer, are able to reduce portal pressure in experimental models of cirrhosis in the rat.
Resveratrol (3,5,4′-trihydroxystilbene) is a natural polyphenolic flavonoid found in a large amount of plant species, including grapes and their derivatives, berries and nuts. It has been suggested to have important health benefits attributed to its demonstrated anti-oxidant, anti-neoplastic, anti-inflammatory and anti-platelet aggregation activities [8], [9], [10], [11]. Specifically, in different experimental models, resveratrol improves vascular dysfunction, an effect that is attributed to its ability to reduce oxidative stress, to upregulate endothelial nitric oxide synthase (eNOS) expression and activity, and to inhibit COX-1 activity [12], [13], [14], [15].
Resveratrol has been shown to exert anti-oxidant effects in experimental models of liver injury induced by ischemia/reperfusion and ethanol by inducing the enzymatic activity of SOD and catalase [16], [17], and to attenuate fibrosis development when co-administered with CCl4 to rats [18]. Additionally, resveratrol reduces the hepatotoxicity induced by acetaminophen, ethanol and carbone tetrachloride (CCl4), and prevents liver damage due to ischemia-reperfusion, irradiation, and high-fat diet [19]. Overall, we hypothesized that resveratrol may exert beneficial effects in the pathophysiological mechanisms involved in the development of portal hypertension in cirrhosis.
Therefore, the aim of the present study was to investigate the effects of chronic administration of resveratrol in CCl4-cirrhotic rats with portal hypertension.
Section snippets
Induction of cirrhosis by CCl4 and resveratrol administration
In male Wistar rats (50–75 g), cirrhosis was induced by inhalation of CCl4 three times a week, and phenobarbital (0.3 g/L) was added to the drinking water as previously described [6]. When cirrhotic rats had developed ascites, after approximately 12–15 weeks of CCl4 inhalation, administration of CCl4 and phenobarbital was discontinued. One week later, the animals were randomized to receive resveratrol (10 mg/kg body weight (bw); Sigma, Tres Cantos, Madrid, Spain) or its vehicle
Effect of resveratrol on hepatic and systemic hemodynamics in cirrhotic rats
Cirrhotic rats receiving long-term treatment with resveratrol (10 mg/kg bw/day) had a significantly lower PP than cirrhotic rats treated with vehicle (12.1 ± 0.9 vs. 14.3 ± 2.2 mmHg; p = 0.02), corresponding to a PP reduction of 15%. No significant changes in PBF, SMABF, MAP or HR were observed (Table 1). Intrahepatic vascular resistance was lower in resveratrol-treated rats, although the difference did not reach statistical significance.
Effect of resveratrol on endothelial function in cirrhotic rat livers
To further characterize the effects of resveratrol on liver
Discussion
In cirrhosis, an increase in hepatic vascular resistance to portal blood flow is the primary factor in the development of portal hypertension [3]. Therefore, it is of great interest to develop therapeutic strategies aimed at decreasing portal pressure by reducing hepatic vascular resistance.
Resveratrol is a natural substance with many biological functions; among others, it induces antioxidant enzymes, increases NO bioavailability and inhibits the production of inflammatory factors [33].
The main
Financial support
This study was supported by grants from the Ministerio de Economía y Competitividad (SAF 2010/17043) and from the Instituto de Salud Carlos III (ACI 2009-0938 and FIS PS09/01261), Spain. Jorge Gracia-Sancho has a Ramón y Cajal contract from the Ministerio de Economía y Competitividad. Ciberehd is funded by the Instituto de Salud Carlos III.
Conflict of interest
The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Acknowledgements
Part of this work was carried out at the Esther Koplowitz Centre, Barcelona.
The authors thank Héctor García and Montse Monclús for experienced technical assistance.
References (43)
- et al.
Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension
J Hepatol
(2010) - et al.
Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension
Gastroenterology
(1998) - et al.
Potential role of antioxidants in the treatment of portal hypertension
J Hepatol
(2007) - et al.
Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers
J Hepatol
(2003) Biological effects of resveratrol
Life Sci
(2000)Molecular mechanism of the chemopreventive effect of resveratrol
Mutat Res
(2003)- et al.
The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease
Clin Chim Acta
(1995) - et al.
Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase
Biochem Biophys Res Commun
(2009) - et al.
Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents
J Biol Chem
(2004) - et al.
Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver
Life Sci
(2007)
Protective effect of resveratrol against oxidative stress in cholestasis
J Surg Res
5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes
Gastroenterology
Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCL(4)-cirrhotic rats
J Hepatol
Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl(4) cirrhotic rats
J Hepatol
Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers
Hepatology
Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers
J Hepatol
PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
J Hepatol
Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses
Biochem Biophys Res Commun
Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests
Life Sci
Cardiovascular effects and molecular targets of resveratrol
Nitric Oxide
Molecular mechanisms of oxidative stress resistance induced by resveratrol: specific and progressive induction of MnSOD
Biochem Biophys Res Commun
Cited by (114)
Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension
2024, Hepatobiliary and Pancreatic Diseases InternationalCandesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF
2023, European Journal of PharmacologyPhenolic compounds in hypertension: Targeting gut-brain interactions and endothelial dysfunction
2023, Journal of Functional FoodsPreservation of vascular endothelial glycocalyx and barrier by activation of adenosine A2A receptor (A<inf>2A</inf>R) improved renal dysfunction in cirrhotic rats
2023, Journal of Pharmacological SciencesHigh throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression
2023, Redox BiologyCitation Excerpt :While this concentration is below the range studied in the present analysis, the direct comparison of serum and local hepatic concentrations may be misleading as the nutritional intake of resveratrol will first yield relatively high local concentrations in liver due to the direct supply via the portal vein, accumulation processes in hepatocytes and enterohepatic cycling [86]. Accordingly, health effects from supplemental resveratrol are consistently observed in models of liver injury, where the stilbenoid accumulates [87,88]. Consecutively, a majority of resveratrol becomes then conjugated with sulphates or glucuronides by hepatic biotransformation yielding a range of secondary metabolites.
- †
These authors contributed equally to this work and share first authorship.